This article is made possible by
Medicines for the treatment of cancer are increasingly being tailored to the patient. But to successfully use those expensive medicines, you also need high-quality technology to make the correct diagnosis.
In this video, Senior Investment Manager Jeroen Siemes of the BOM and CEO and co-founder Paul van de Wiel discuss the collaboration between the Brabantse Ontwikkelings Maatschappij (BOM) and InnoSIGN, a spin-out from Philips that uses an mRNA test in combination with a data analysis platform. This makes it possible to predict how patients respond to targeted personal therapies.
More information about the collaboration between BOM and InnoSIGN can be found here (in Dutch).
